Dyne Therapeutics

Historical price data

Dyne Therapeutics is executing a focused strategy to become a leader in precision genetic medicine for muscle diseases. The company's core achievement is the development of its FORCE™ platform, an antibody-oligonucleotide conjugate technology designed for muscle-specific delivery, which has now propelled three lead candidates into clinical trials. Its strategy targets large, validated genetic indications—myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD)—with the goal of demonstrating superior efficacy and tolerability. With a cash runway extending into 2026, Dyne is well-positioned to generate critical clinical proof-of-concept data across its pipeline.

The FORCE™ platform is a proprietary antibody-oligonucleotide conjugate (AOC) system engineered for targeted delivery of therapeutic oligonucleotides to muscle tissue by binding to the transferrin receptor 1 (TfR1).

Dyne faces competition from approved exon-skipping therapies (Sarepta) in DMD and various oligonucleotide/gene therapy approaches in DM1 and FSHD. Its key differentiator is the muscle-targeted delivery of its FORCE™ platform, aiming for superior efficacy and tolerability compared to systemic approaches.